Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity
2024-511511-25-00Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Dec 2024
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, tremelimumab and cisplatin in Oral Mucosal Carcinoma, sponsored by UZ Leuven. Primary endpoint: CD8 infiltration in the tumor. Started Dec 2024; status: completed.
02
Drugs
durvalumabtremelimumabcisplatin
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2024-511511-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511511-25-00.